In the BioHarmony Drug Report Database
Uroxatral (alfuzosin) is a small molecule pharmaceutical. Alfuzosin was first approved as Uroxatral on 2003-06-12. It is used to treat prostatic hyperplasia in the USA. The pharmaceutical is active against alpha-1B adrenergic receptor, alpha-1D adrenergic receptor, and alpha-1A adrenergic receptor.
Image (chem structure or protein)